Macrogenics (MGNX) Cash from Financing Activities (2012 - 2026)
Macrogenics (MGNX) reported Cash from Financing Activities of -$207000.0 for Q1 2026, up 26.6% year-over-year from -$163512.6 in Q1 2025, and down 463.16% quarter-over-quarter from $57000.0 in Q4 2025.
Macrogenics (MGNX) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 15 years of Cash from Financing Activities data on file, last reported at -$207000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$207000.0, up 26.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.6 million (up 16083.49% YoY), and the FY2025 annual result was $69.5 million, up 7141.04% from the prior year.
- Cash from Financing Activities slipped to -$207000.0 in Q1 2026 per MGNX's latest filing, from $57000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $100.1 million in Q1 2023 and troughed at -$282000.0 in Q1 2025.
- A 5-year average of $14.8 million and a median of $248000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities soared 270489.19% in 2023, then tumbled 213.71% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $1.4 million in 2022, then tumbled by 79.91% to $273000.0 in 2023, then plunged by 43.22% to $155000.0 in 2024, then slumped by 63.23% to $57000.0 in 2025, then slumped by 463.16% to -$207000.0 in 2026.
- Business Quant data shows MGNX's Cash from Financing Activities at -$207000.0 in Q1 2026, $57000.0 in Q4 2025, and $69.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | -207,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -207,000.00 |
| Mar 31, 2026 | -207,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Jun 30, 2025 | 69.74 Mn |
| Jun 30, 2025 | 69.74 Mn |
| Mar 31, 2025 | -282,000.00 |
| Mar 31, 2025 | -282,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Dec 31, 2024 | 155,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Sep 30, 2024 | -68,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Mar 31, 2024 | 248,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Dec 31, 2023 | 273,000.00 |
| Sep 30, 2023 | 49.91 Mn |
| Sep 30, 2023 | 49.91 Mn |